{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:28:16Z","timestamp":1780565296292,"version":"3.54.1"},"reference-count":28,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.59556\/japi.74.1439","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:37:03Z","timestamp":1773380223000},"page":"103-107","source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide Hype or Hope: Evidence-based Review in Diabesity"],"prefix":"10.59556","volume":"74","author":[{"given":"Sunil","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brij Mohan","family":"Makkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(3):","key":"key20260313053659_B1","first-page":"315\u2013","article-title":"Prevalence and factors influencing diabesity among persons with type 2 diabetes mellitus in urban Puducherry: a cross-sectional analytical study.","volume":"45","author":"Rehman","year":"2020;","journal-title":"Indian J Community Med"},{"issue":"(7):","key":"key20260313053659_B2","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260313053659_B3","first-page":"100204.","article-title":"Trends and insights from the National Family Health Surveys.","volume":"12:","author":"Jindal","year":"2025;","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"(7):","key":"key20260313053659_B4","doi-asserted-by":"crossref","first-page":"481\u2013","DOI":"10.7326\/0003-4819-122-7-199504010-00001","article-title":"Weight gain as a risk factor for clinical diabetes mellitus in women.","volume":"122","author":"Colditz","year":"1995;","journal-title":"Ann Intern Med"},{"issue":"(9):","key":"key20260313053659_B5","doi-asserted-by":"crossref","first-page":"961\u2013","DOI":"10.2337\/diacare.17.9.961","article-title":"Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.","volume":"17","author":"Chan","year":"1994;","journal-title":"Diabetes Care"},{"issue":"(1):","key":"key20260313053659_B6","first-page":"1\u2013","article-title":"RSSDI clinical practice recommendations for management of type 2 diabetes mellitus 2022.","volume":"42","author":"Makkar","year":"2022;","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"(Suppl 1):","key":"key20260313053659_B7","first-page":"S1\u2013","article-title":"Introduction and methodology: standards of care in diabetes\u20142026.","volume":"49","author":"Bajaj","year":"2026;","journal-title":"Diabetes Care"},{"issue":"(Suppl 1):","key":"key20260313053659_B8","first-page":"S158\u2013","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024.","volume":"47","author":"ElSayed","year":"2024;","journal-title":"Diabetes Care"},{"key":"key20260313053659_B9","author":"Schroeder","year":"2022.","journal-title":"Management of type 2 diabetes: selecting amongst available pharmacological agents."},{"issue":"(5):","key":"key20260313053659_B10","doi-asserted-by":"crossref","first-page":"341\u2013","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.","volume":"5","author":"Ahr\u00e9n","year":"2017;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(19):","key":"key20260313053659_B11","doi-asserted-by":"crossref","first-page":"1834\u2013","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016;","journal-title":"N Engl J Med"},{"issue":"(6):","key":"key20260313053659_B12","doi-asserted-by":"crossref","first-page":"2291\u2013","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.","volume":"103","author":"Rodbard","year":"2018;","journal-title":"J Clin Endocrinol Metab"},{"key":"key20260313053659_B13","volume-title":"WHO updates list of essential medicines to include key cancer, diabetes treatments.","author":"World Health Organization.","year":"2025."},{"issue":"(4):","key":"key20260313053659_B14","doi-asserted-by":"crossref","first-page":"251\u2013","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.","volume":"5","author":"Sorli","year":"2017;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(5):","key":"key20260313053659_B15","doi-asserted-by":"crossref","first-page":"355\u2013","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.","volume":"5","author":"Aroda","year":"2017;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(2):","key":"key20260313053659_B16","doi-asserted-by":"crossref","first-page":"258\u2013","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial.","volume":"41","author":"Ahmann","year":"2018;","journal-title":"Diabetes Care"},{"issue":"(11):","key":"key20260313053659_B17","doi-asserted-by":"crossref","first-page":"2891\u2013","DOI":"10.1007\/s13300-021-01141-8","article-title":"Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective, observational study.","volume":"12","author":"Holmes","year":"2021;","journal-title":"Diabetes Ther"},{"issue":"(3):","key":"key20260313053659_B18","doi-asserted-by":"crossref","first-page":"399.","DOI":"10.3390\/ph18030399","article-title":"Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment.","volume":"18","author":"Salvador","year":"2025;","journal-title":"Pharmaceuticals"},{"issue":"(3):","key":"key20260313053659_B19","doi-asserted-by":"crossref","first-page":"153\u2013","DOI":"10.2337\/ds017-0025","article-title":"Why weight loss maintenance is difficult.","volume":"30","author":"Evert","year":"2017;","journal-title":"Diabetes Spectr"},{"issue":"(2):","key":"key20260313053659_B20","doi-asserted-by":"crossref","first-page":"109\u2013","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.","volume":"391","author":"Perkovic","year":"2024;","journal-title":"N Engl J Med"},{"issue":"(10):","key":"key20260313053659_B21","doi-asserted-by":"crossref","first-page":"2849\u2013","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.","volume":"30","author":"Mann","year":"2024;","journal-title":"Nat Med"},{"issue":"(10):","key":"key20260313053659_B22","doi-asserted-by":"crossref","first-page":"776\u2013","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019;","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"(10489):","key":"key20260313053659_B23","doi-asserted-by":"crossref","first-page":"1580\u2013","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.","volume":"405","author":"Bonaca","year":"2025;","journal-title":"Lancet"},{"issue":"(10322):","key":"key20260313053659_B24","doi-asserted-by":"crossref","first-page":"394\u2013","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.","volume":"399","author":"Lingvay","year":"2022;","journal-title":"Lancet"},{"issue":"(4):","key":"key20260313053659_B25","doi-asserted-by":"crossref","first-page":"311\u2013","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016;","journal-title":"N Engl J Med"},{"issue":"(10193):","key":"key20260313053659_B26","doi-asserted-by":"crossref","first-page":"121\u2013","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019;","journal-title":"Lancet"},{"issue":"(24):","key":"key20260313053659_B27","doi-asserted-by":"crossref","first-page":"2221\u2013","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023;","journal-title":"N Engl J Med"},{"issue":"(8):","key":"key20260313053659_B28","doi-asserted-by":"crossref","first-page":"3634\u2013","DOI":"10.1007\/s12325-025-03250-3","article-title":"An overview of currently available injectable therapies in diabetes: a guide to practitioners.","volume":"42","author":"Kesavadev","year":"2025;","journal-title":"Adv Ther"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:37:07Z","timestamp":1773380227000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-3-103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.59556\/japi.74.1439"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1439","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}